NEW YORK – After several years of refining and optimizing its assay platform, epigenetic diagnostic firm VolitionRx is nearing its first implementation in cancer detection, while also eyeing a detour in infectious disease spurred by the emerging coronavirus pandemic.
Get the full story with
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.